Thursday, 28 July 2011
David Brennan, Chief Executive Officer said:
"Despite the anticipated impact of generic competition and government pricing interventions in the quarter, we are able to raise our Core earnings per share guidance and increase our shareholder cash return targets for the full year. The approval of Brilinta in 41 countries around the world, most recently in the US, demonstrates our commitment to deliver our global, innovation-driven biopharmaceuticals strategy."
Second quarter and half year results 2011
Announced on Thursday 28 July 2011
- Cautionary statement regarding forward looking statements (PDF 56kb)
- Narrative (PDF 484kb)
- Figures (PDF 1268kb)
- Pipeline table (PDF 325kb)
Downloads
- Presentation (PDF 886kb)
- David Brennan, Chief Executive Officer script (PDF 82kb)
- Simon Lowth, Chief Financial Officer script (PDF 90kb)
- Martin Mackay, President R&D analyst script (PDF 116kb)